Collins F M
Laboratory of Mycobacteria, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20852, USA.
Front Biosci. 1998 Jul 23;3:e123-32. doi: 10.2741/a285.
Tuberculosis is an age-old human affliction which continues to flourish worldwide despite the development of effective drugs for its treatment and a vaccine (BCG) for its prevention. At least 8 million people die from this disease each year, a figure which is likely to increase as the AIDS epidemic continues its relentless spread into Africa and Southeast Asia. Consumption was shown to be caused by Mycobacterium tuberculosis more than a century ago, yet we still know very little about the mechanisms used by this organism to elude the normally effective cellular host defenses as it establishes a progressive infection within the lung. The majority of individuals exposed to tuberculous infection are able to limit the primary infection to the lungs and its lymph nodes, resulting in a latent form of the disease which can provide the host with a lifelong immunity to reinfection. While a great deal is known about the cellular mediators of this immune response (together with the cytokines which modulate them) we lack a clear understanding of the role that they play during the establishment of the dormant form of the disease. Live BCG vaccine has been widely used in many Third World countries as a major component of their tuberculosis control programs. However, several carefully controlled human trials have shown little protection achieved in vaccinated individuals. Development of improved vaccines, both for the prevention and therapy of this disease is an urgent research priority and a number of potential immunogens are under active investigation. However, our limited understanding of the pathogenesis of this chronic disease, together with a lack of data on the role played by different bacterial components in the modulation of the immune response, continues to severely limit our ability to develop a rational approach to this project. To achieve this goal, it will be necessary to establish innovative approaches to the presentation of protective antigens by taking advantage of recent advances in the molecular biology of this complex and enigmatic group of organisms.
结核病是一种古老的人类疾病,尽管已经开发出有效的治疗药物和预防疫苗(卡介苗),但它仍在全球范围内肆虐。每年至少有800万人死于这种疾病,随着艾滋病疫情在非洲和东南亚持续无情蔓延,这一数字可能还会上升。一个多世纪前就已证明,肺结核是由结核分枝杆菌引起的,但对于这种病原体在肺部建立进行性感染时,是如何逃避通常有效的细胞宿主防御机制的,我们仍然知之甚少。大多数接触结核菌感染的个体能够将原发性感染局限于肺部及其淋巴结,从而形成疾病的潜伏形式,这种潜伏形式可为宿主提供终身的再感染免疫力。虽然我们对这种免疫反应的细胞介质(以及调节它们的细胞因子)了解很多,但对于它们在疾病潜伏形式形成过程中所起的作用,我们还缺乏清晰的认识。活卡介苗已在许多第三世界国家广泛用作其结核病控制计划的主要组成部分。然而,几项精心控制的人体试验表明,接种疫苗的个体几乎没有获得保护。开发用于预防和治疗这种疾病的改进疫苗是当务之急,许多潜在的免疫原正在积极研究中。然而,我们对这种慢性病发病机制的了解有限,加上缺乏关于不同细菌成分在调节免疫反应中所起作用的数据,仍然严重限制了我们制定合理方案开展该项目的能力。为实现这一目标,有必要利用这一复杂而神秘的生物体分子生物学的最新进展,建立呈现保护性抗原的创新方法。